Mild cognitive impairment: At the crossroad of neurodegeneration and vascular dysfunction

Current Alzheimer Research

Volumn 12, Issue 6, 2015, Pages 507-512

  Saito, Satoshi ^a   Yamamoto, Yumi ^a   Ihara, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Alzheimer s disease; Cerebral amyloid angiopathy; Cerebrovascular disease; Cilostazol; Diagnosis; Microinfarcts; Mild cognitive impairment; Neurocognitive disorder

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ARTERIOSCLEROSIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE; COMPLICATION; DEGENERATIVE DISEASE;

CEREBROVASCULAR DISORDERS; DISEASE PROGRESSION; HUMANS; MILD COGNITIVE IMPAIRMENT; NEURODEGENERATIVE DISEASES;

EID: 84938599853     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150530202508     Document Type: Article

References (91)

1. Pimentel-Coelho PM, Rivest S. The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease. Eur J Neurosci 35(12): 1917-37 (2012).
2. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62(7): 1160-3; discussion 67 (2005).
3. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2(8): 646-53 (2003).
4. Panza F, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 13(8): 633-44 (2005).
5. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 367(9518): 1262-70 (2006).
6. Manly JJ, Bell-McGinty S, Tang MX, Schupf N, Stern Y, Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 62(11): 1739-46 (2005).
7. Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand 106(3): 148-54 (2002).
8. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 60(10): 1385-9 (2003).
9. Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC. Mild cognitive impairment: incidence and vascular risk factors in a populationbased cohort. Neurology 80(23): 2112-20 (2013).
10. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 16(2): 129-40 (2004).
11. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol 66(12): 1447-55 (2009).
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3): 303-8 (1999).
13. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3): 183-94 (2004).
14. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 58(12): 1985-92 (2001).
15. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 270-9 (2011).
16. Budson AE, Solomon PR. New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist. Pract Neurol 12(2): 88-96 (2012).
17. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3): 349-56 (2012).
18. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol 2(2): 89-98 (2003).
19. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42(9): 2672-713 (2011).
20. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol 10(11): 634-42 (2014).
21. Vega JN, Newhouse PA. Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep 16(10): 490 (2014).
22. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69(1): 181-92 (2011).
23. Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, et al. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. Neurobiol Aging 35(1): 143-51 (2014).
24. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, et al. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123(1): 13-30 (2012).
25. Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology 27(6): 578-84 (2007).
26. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63(5): 674-81 (2006).
27. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 263-9 (2011).
28. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in communitydwelling older persons. Neurology 69(24): 2197-204 (2007).
29. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277(10): 813-7 (1997).
30. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6(11): e1000180 (2009).
31. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66(2): 200-8 (2009).
32. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64(5): 834-41 (2005).
33. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 136(Pt 9): 2697-706 (2013).
34. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 32(3): 425-36 (2012).
35. Okamoto Y, Ihara M, Fujita Y, Ito H, Takahashi R, Tomimoto H. Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport 20(11): 990-6 (2009).
36. Okamoto Y, Yamamoto T, Kalaria RN, Senzaki H, Maki T, Hase Y, et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 123(3): 381-94 (2012).
37. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054): 184-5 (1992).
38. Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke 43(9): 2526-34 (2012).
39. Keage HA, Carare RO, Friedland RP, Ince PG, Love S, Nicoll JA, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol 9: 3 (2009).
40. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357(9251): 169-75 (2001).
41. Westover MB, Bianchi MT, Yang C, Schneider JA, Greenberg SM. Estimating cerebral microinfarct burden from autopsy samples. Neurology 80(15): 1365-9 (2013).
42. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 11(3): 272-82 (2012).
43. Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol 70(5): 774-80 (2011).
44. Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 62(4): 406-13 (2007).
45. van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, Spliet WG, Hendrikse J, Luijten PR, et al. In vivo detection of cerebral cortical microinfarcts with high-resolution 7T MRI. J Cereb Blood Flow Metab 33(3): 322-9 (2013).
46. van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb AG, Blauw GJ, et al. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology 270(1): 205-11 (2014).
47. Ii Y, Maeda M, Kida H, Matsuo K, Shindo A, Taniguchi A, et al. In vivo detection of cortical microinfarcts on ultrahigh-field MRI. J Neuroimaging 23(1): 28-32 (2013).
48. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 83(2): 124-37 (2012).
49. Haller S, Bartsch A, Nguyen D, Rodriguez C, Emch J, Gold G, et al. Cerebral microhemorrhage and iron deposition in mild cognitive impairment: susceptibility-weighted MR imaging assessment. Radiology 257(3): 764-73 (2010).
50. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9(7): 689-701 (2010).
51. Tanoi Y, Okeda R, Budka H. Binswanger's encephalopathy: serial sections and morphometry of the cerebral arteries. Acta Neuropathol 100(4): 347-55 (2000).
52. Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol 39(6): 593-611 (2013).
53. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12): 723-38 (2011).
54. Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, et al. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res 1294: 202-10 (2009).
55. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 103(49): 18727- 32 (2006).
56. Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 30(7): 1091-8 (2009).
57. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gammasecretase inhibition. J Neurosci 28(50): 13542-50 (2008).
58. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38(1): 24-6 (2006).
59. Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117(1): 1-14 (2009).
60. Ngandu T, von Strauss E, Helkala EL, Winblad B, Nissinen A, Tuomilehto J, et al. Education and dementia: what lies behind the association? Neurology 69(14): 1442-50 (2007).
61. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7(9): 812-26 (2008).
62. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 5(12): 649-58 (2009).
63. Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci 5: 64 (2013).
64. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 322(1-2): 141-7 (2012).
65. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73(9): 674-80 (2009).
66. Langa KM, Larson EB, Karlawish JH, Cutler DM, Kabeto MU, Kim SY, et al. Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? Alzheimers Dement 4(2): 134-44 (2008).
67. Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twentyyear changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 80(20): 1888-94 (2013).
68. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 78(19): 1456-63 (2012).
69. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med 369(24): 2275-7 (2013).
70. Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 382(9902): 1405-12 (2013).
71. Boyle PA, Buchman AS, Wilson RS, Kelly JF, Bennett DA. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 34(1): 43-9 (2010).
72. Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol 165(11): 1231-8 (2007).
73. Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol 60(10): 1394-9 (2003).
74. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol 64(12): 1734-40 (2007).
75. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 58(4): 643-7 (2001).
76. Das SK, Bose P, Biswas A, Dutt A, Banerjee TK, Hazra AM, et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 68(23): 2019-26 (2007).
77. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 65(8): 1066-73 (2008).
78. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. Cardiac disease associated with increased risk of nonamnestic cognitive impairment: stronger effect on women. JAMA Neurol 70(3): 374-82 (2013).
79. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63(10): 1882-91 (2004).
80. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc 61(1): 67-73 (2013).
81. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76(17): 1485-91 (2011).
82. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol 9(10): 959-68 (2010).
83. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: A placebo-controlled doubleblind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9(4): 147-57 (2000).
84. Maki T, Okamoto Y, Carare RO, Hase Y, Hattori Y, Hawkes CA, et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular beta-amyloid. Ann Clin Transl Neurol 1(8): 519-33 (2014).
85. Saito S, Ihara M. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 6: 290 (2014).
86. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012): 1774 (2010).
87. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 118(1): 87-102 (2009).
88. Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, Nishino M, et al. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. Psychogeriatrics 13(3): 164-69 (2013).
89. Ihara M, Nishino M, Taguchi A, Yamamoto Y, Hattori Y, Saito S, et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. PLoS One 9(2): e89516 (2014).
90. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 203(3): 255-64 (2013).
91. Garrison FH. The literary tradition in english medicine, (with sidelights on medicine in english literature). Bull N Y Acad Med 8(9): 535-57 (1932).